Comparison of treament and efficacy in different uveitis subtypes
| Uveitis location | Efficacy | During treatment with adalimumab* | Previous anti-TNF treatment with insufficient response | ||
|---|---|---|---|---|---|
| None | Etanercept† | Infliximab‡ | |||
| Primary anterior uveitis | Effective | 4 (80%) | 3 | 1 | 0 |
| Non-effective | 1 (20%) | 1 | 0 | 0 | |
| Anterior uveitis and SpA | Effective | 19 (86%) | 10 | 4 | 5 |
| Non-effective | 2 (14%) | 1 | 0 | 1 | |
| Anterior uveitis and JIA | Effective | 13 (76%) | 8 | 3 | 2 |
| Non-effective | 4 (24%) | 3 | 1 | 0 | |
| Anterior uveitis and PsA | Effective | 3 (75%) | 0 | 3 | 0 |
| Non-effective | 1 (25%) | 0 | 1 | 0 | |
| Intermediate uveitis§ | Effective | 5 (100%) | 4 | 0 | 1 |
| Non-effective | 0 (0%) | 0 | 0 | 0 | |
| Panuveitis¶ | Effective | 3 (100%) | 1 | 1 | 1 |
| Non-effective | 0 (0%) | 0 | 0 | 0 | |
| Others** | Effective | 2 (40%) | 1 | 1 | 0 |
| Non-effective | 3 (60%) | 3 | 0 | 0 | |
| 60 (100%) | 35 (58.3%) | 15 (25.0%) | 10 (16.7%) | ||
*40 mg injection subcutaneously every other week.
†25 mg injection twice a week.
‡3–5 mg/kg bodyweight—starting with upload.
§One patient with intermediate uveitis and rheumatoid arthritis, four patients without systemic disease.
¶One patient with Behçet's, two patients without systemic disease.
**One patient with Behçet's and anterior uveitis (non-effective), two patients with anterior uveitis and rheumatoid arthritis (non-effective) and two patients with scleritis (effective).
JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; SpA, spondylarthropathy; TNF, tumour necrosis factor.